1618 Station Street Vancouver, BC V6A 1B6 Canada [t] 001 604 221 7676 [f] 001 604 221 2330
Angiotech Pharmaceuticals is a global specialty pharmaceutical and medical device company.
Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.
Angiotech Pharmaceuticals has launched Quill SRS Monoderm, which is a rapidly resorbing polymer intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate.
Angiotech Pharmaceuticals has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the USA.
Angiotech Pharmaceuticals and Symphony Medical have entered into an exclusive licensing agreement to employ one of Angiotech's proprietary PEG-based biomaterials as part of a prophylactic therapy that mitigates the onset of post-operative atrial fibrillation (POAF) for patients undergoing coronary artery bypass grafting and cardiac valve surgeries.
